Japanese patch drug powerhouse Hisamitsu Pharmaceutical was slapped with a business suspension order on August 12 for falsifying data in the manufacturing process of one of the OTC products among its mainstay Salonpas series of topical anti-inflammatory analgesics. The government…
To read the full story
Related Article
- JPMA Suspends Ono’s Membership over Onoact Bribery Case
September 17, 2021
BUSINESS
- Eisai to Discontinue Tazverik in Japan over Secondary Cancer Risk
March 19, 2026
- BMS, Nikon Eye Full Domestic CAR-T Manufacturing in Japan from 2027
March 19, 2026
- Blenrep, Monjuvi, Zynyz, and More New Drugs Hit Japan Market
March 19, 2026
- Celltrion, CMIC Forge Broad Partnership in Japan Biosimilars Business
March 19, 2026
- J&J Launches Nurse-Led Support Program for Lung Cancer Patients in Japan
March 19, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





